Type 1 diabetes mellitus
Conditions
Interventions
Group 2:dapagliflozin 10mg qd
Group 1:Acarbose 50mg tid
Sponsors
Department of Endocrinology, the First Affiliated Hospital of Shantou University Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Diagnosed type 1 diabetes, age 18-60 years old, using insulin to control blood glucose
Exclusion criteria
Exclusion criteria: (1) pregnant or planned pregnancy, breast-feeding; (2) renal insufficiency (eGFR < 60ml/min/1.73m2); (3) diabetes ketosis or ketoacidosis occurred in the last 3 months; (4) urinary tract infection or genital infection; (5) Alpha-Glucosidase Inhibitor or SGLT-2 Inhibitor had been used in the last three months of treatment. Those who were previously known to be intolerable to Alpha-Glucosidase Inhibit or SGLT-2 Inhibitor; (6) Severe liver dysfunction or other important organ dysfunction (such as cardiac insufficiency, chronic respiratory failure, etc.) and severe anemia; (7) Those who had acute myocardial infarction, cerebrovascular accident and severe infection within one month before admission to the group; (8) Using glucocorticoids and other drugs that affect blood glucose; (9) those who underwent surgery during the planned study period; (10) Allergies to medical adhesives or alcohol for disinfection; (11) Local skin damage, scarring, infection, edema or other skin lesions on the application site; (12) Patient with a history of mental illness or other conditions who can not wear sensors as required; (13) Those who fail to follow the research plan and carry out research tasks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mean amplitude of glycemic excursions; | — |
Countries
China
Contacts
Public ContactShaoda Lin
The First Affiliated Hospital of Shantou University Medical College
Outcome results
None listed